

CrossMark
click for updatesCite this: *J. Mater. Chem. B*, 2014, 2,
6723

Bacteria repelling poly(methylmethacrylate-co-dimethylacrylamide) coatings for biomedical devices†

Seshasailam Venkateswaran,^{‡a} Mei Wu,^{‡a} Peter J. Gwynne,^b Ailsa Hardman,^b
Annamaria Lilienkamp,^a Salvatore Pernagallo,^a Garry Blakely,^b David G. Swann,^c
Maurice P. Gallagher^{*b} and Mark Bradley^{*a}

Nosocomial infections due to bacteria have serious implications on the health and recovery of patients in a variety of medical scenarios. Since bacterial contamination on medical devices contributes to the majority of nosocomial infections, there is a need for redesigning the surfaces of medical devices, such as catheters and tracheal tubes, to resist the binding of bacteria. In this work, polyurethanes and polyacrylates/acrylamides, which resist binding by the major bacterial pathogens underpinning implant-associated infections, were identified using high-throughput polymer microarrays. Subsequently, two 'hit' polymers, PA13 (poly(methylmethacrylate-co-dimethylacrylamide)) and PA515 (poly(methoxyethylmethacrylate-co-diethylaminoethylacrylate-co-methylmethacrylate)), were used to coat catheters and substantially shown to decrease binding of a variety of bacteria (including isolates from infected endotracheal tubes and heart valves from intensive care unit patients). Catheters coated with polymer PA13 showed up to 96% reduction in bacteria binding in comparison to uncoated catheters.

Received 10th July 2014
Accepted 19th August 2014

DOI: 10.1039/c4tb01129e

www.rsc.org/MaterialsB

Introduction

Nosocomial or hospital related infections, *i.e.*, infection acquired by a patient who was initially admitted for a reason other than infection, are widespread in patients in intensive care units and those requiring long-term catheter use. It has been estimated that in the US 1.7 million patients acquire a nosocomial infection each year, resulting in over 90 000 deaths.¹ In the UK, one in ten patients acquire a nosocomial infection costing the economy >£1 billion per year.² These infections pose major issues for patient care, which are further complicated by the emergence of global antibiotic resistant organisms.

Bacteria account for the majority of nosocomial infections³ and adhesion of bacteria to a surface, such as a catheter, is an essential step in the process.⁴ Moreover, bacteria on a surface provide a source for reseeding infection, once established in a biofilm.⁵ Initial bacterial adhesion is affected by the relative charge and hydrophobicity of the surface, and by chemical interactions between the bacteria and the surface and/or secreted components and/or components of biological fluids on the surface.^{6–8} Attachment is followed by production of extracellular polysaccharides and proteins by the bacteria, as the biofilm establishes.⁷ The biofilm provides a physical barrier against both the host immune system and antimicrobial therapy, and bacteria within biofilms can have >1000-fold higher resistance to some antibiotics as compared to planktonic bacteria.⁹ As biofilms are involved in the majority of microbial infections, including chronic infections, prevention of biofilm formation is important in a clinical setting.¹⁰

Since medical devices often contribute to nosocomial infections,¹¹ there is an interest to render the surface of these devices resistant to bacterial adhesion and biofilm formation.¹² As such, the surface of a medical device can be crafted to contain agents, including antibiotics or bactericides (*e.g.* silver, iodine or surfactants).^{13–17} These modified surfaces prevent colonisation by killing bacteria on contact or by the release of antimicrobials in the area surrounding the medical device. When suboptimal, this approach is not ideal since it can contribute to the emergence of resistant strains.¹⁴ In addition, some of the agents used on the crafted surfaces are expensive and may not be suitable

^aSchool of Chemistry, EaStCHEM, University of Edinburgh, King's Buildings, West Mains Road, Edinburgh, EH9 3JJ, UK. E-mail: mark.bradley@ed.ac.uk; Tel: +44 (0) 131 650 4820

^bSchool of Biological Sciences, University of Edinburgh, King's Buildings, West Mains Road, Edinburgh, EH9 3JF, UK. E-mail: mp.gallagher@ed.ac.uk; Tel: +44 (0)131 650 5409

^cCritical Care, NHS Lothian, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh, EH16 4SA, UK

† Electronic supplementary information (ESI) available: Polymer microarray screening, including analysis of bacterial adhesion by fluorescence microscopy and SEM, and chemical composition of bacteria repelling polymers identified in the screen; polymer synthesis and characterisation; preparation of catheter pieces and solvent studies, and details for confocal imaging/analysis. See DOI: 10.1039/c4tb01129e

‡ Equal contribution.



for use with all patients as they may elicit allergic reactions.⁷ A more attractive alternative to prevent bacterial adhesion would be to coat the medical device with a polymer, which inherently resists adhesion of bacteria.¹⁸

The traditional approaches for the discovery of polymer-based biomaterials with new properties are time-consuming and iterative, involving sequential study of individual polymer for the desired properties, followed by their structural optimisation. As an alternative approach, well-plate based screening methods have been used to identify bacteria-repelling surfaces.^{19,20} For example, a well-plate based assay allowed the comparison of adhesion of *Staphylococcus aureus* (*S. aureus*) on synthetic and biologically derived surgical materials used in plastic surgery.²¹ However, well-plate based methods are typically limited to relatively small number of surfaces to be assessed in parallel. To enable a high-throughput approach to the discovery of new biomaterials, Bradley²² and Langer²³ have developed polymer microarray platforms. These have resulted in the identification of biomaterials by Bradley for various applications such as for the long-term culture of mouse embryonic stem cells,²⁴ culture of human embryonic stem cells and mesenchymal stem cells with thermal harvesting,^{25,26} and the activation of platelets.²⁷ In addition, polymer microarrays have been used to identify materials able to capture or prevent the binding of *Escherichia coli*, the major food-borne pathogen *Salmonella enterica* serovar *Typhimurium*,²⁸ *Pseudomonas aeruginosa*, *Escherichia coli* and *S. aureus*,²⁹ and the protozoan parasites *Giardia lamblia*³⁰ and *Cryptosporidium parvum*.³¹

The aim of this study was to utilise polymer microarrays to identify polymers with anti-adhesive characteristics against a range of clinically important Gram-negative and Gram-positive bacteria. Thus, a library of 381 polyacrylates/acrylamides and polyurethanes was screened for their ability to reduce/prevent attachment of a range of major bacterial pathogens including *Campylobacter jejuni* (*C. jejuni*), *Clostridium difficile* (*C. difficile*), *Clostridium perfringens* (*C. perfringens*), *Streptococcus mutans* (*S. mutans*), *Klebsiella pneumoniae* (*K. pneumoniae*), *Staphylococcus saprophyticus* (*S. saprophyticus*), *Enterococcus faecalis* (*E. faecalis*) and *S. aureus* either individually or in microbial 'cocktails'. Key bacteria repellent 'hit' polymers, identified using the microarray screens, were scaled-up and their ability to resist bacterial attachment was confirmed on larger surfaces. Two polymers were chosen for detailed study and used to coat two types of commercially available intravenous catheters. Confocal microscopy and scanning electron microscopy (SEM) analysis were used to study and quantify bacteria binding on the coated and uncoated catheters.

Materials and methods

All chemicals were of analytical grade and used without further purification. Sodium cacodylate trihydrate, formaldehyde, monomers for polymer synthesis, and silane-prep glass slides were purchased from Sigma-Aldrich. Glutaraldehyde (2.5% w/v) and osmium tetroxide (1% w/v) were from Electron Microscopy Sciences. Well plates were purchased from Nunc, glass coverslips from VWR, and GeneFrames from Thermo Scientific.

Polyurethane large bore multi-lumen central intravenous catheterisation sets (**Cath-1**) were purchased from Arrow International (CS12123E), and silicone double lumen catheter sets with stylet (**Cath-2**) from Baxter Healthcare Corporation (ECS1320).

Polymer synthesis and characterisation

For coating of the catheters, **PA13** (M_w 411 kDa, PDI 3.4), **PA515** (M_w 90 kDa, PDI 2.7) and **PA155** (M_w 9.5 kDa, PDI 1.2) were synthesised by free-radical polymerisation and characterised by gel permeation chromatography (GPC) and infrared spectroscopy (IR) (see ESI†). GPC was conducted on an Agilent GPC instrument, fitted with a PLgel 5 μ m MIXED-C column (300 \times 7.5 mm), with NMP as eluent (flow rate 1 mL min⁻¹), pre-calibrated using polystyrene standards. IR analysis was conducted using a Bruker Tensor 27 spectrometer.

Coating of the catheters

Depending on the concentration/viscosity of the polymer solutions, two methods of coating were employed, with polymer loading confirmed by increase in weight of the catheter pieces after coating and drying (ESI†). For the binding studies by confocal microscopy, 2.5% polymer solutions in acetone (w/v) were used. The catheter pieces were placed into a small glass vial (5 mL) and 1 mL of the polymer solution was added for 2 min. The excess polymer solution was removed and the catheter pieces were dried overnight *in vacuo* at 40 °C. For the SEM studies, catheter coating was achieved by immersing the pieces into 10% **PA13** solution in acetone (w/v) for ~30 seconds. The coated pieces were air dried for 30 min and then re-coated by immersing into the polymer solution. The pieces were dried overnight at room temperature.

Preparation of bacteria and seeding on catheters

K. pneumoniae, *S. saprophyticus*, *S. aureus*, *E. faecalis*, and *S. mutans* were cultured on agar-coated Petri dishes with brain-heart-infusion (BHI) medium in a microaerobic environment (85% N₂, 10% CO₂, 5% O₂) at 37 °C. For *S. mutans* strain NCTC 10923 was used. All other strains were clinical isolates obtained from infected medical devices and identified by PCR genotyping. Frozen stock of the bacteria was prepared and used for all experiments, to enable seeding known count of bacteria and ensuring consistency between experiments. For preparing the frozen stocks, overnight cultures of each strain were set up: bacteria were inoculated into 50 mL of BHI and incubated in a Falcon tube in a microaerobic environment at 37 °C for 12 h, except for *S. mutans*, which was incubated for 36 h. Cultures were frozen after addition of 10% glycerol, and the number of colony forming units (CFU) per mL in the frozen stock determined through serial dilution.

For the catheter experiments, BacMix-1 and BacMix-2 were prepared from frozen stocks. BacMix-1 was prepared with *K. pneumoniae*, *S. saprophyticus*, and *S. aureus*, approximately 5×10^5 CFU of each bacteria in 50 mL of BHI medium. BacMix-2 was prepared with *K. pneumoniae*, *S. mutans*, *S. aureus*, and *E. faecalis*, with all the strains other than *S. mutans* maintained at 5×10^5 CFU per 50 mL of BHI medium. Due to its lower



proliferation rate, *S. mutans* was seeded in approximately 2-fold higher density.

For studies *via* confocal microscopy, pieces ($n = 3$) of uncoated catheters **Cath-1** and **Cath-2**, those coated with polymers **PA13**, **PA515** or control **PA155** were placed in agarose coated 24-well plates, sterilised by UV (20 min), and inoculated with 1 mL of either BacMix-1 or BacMix-2. After seeding, the plates were incubated for 72 h in a microaerobic environment at 37 °C, with agitation at 50 rpm. The media was supplemented with 0.5 mL of BHI at 24 h and 48 h. For quantification of bacterial binding using SEM, catheters were seeded with 2 mL of bacterial stocks and incubated in medium for 12 days with agitation at 50 rpm.

Quantification of bacteria binding

Confocal microscopy analysis. Catheter samples ($n = 3$) were washed with PBS (2×2 mL) after incubation with bacteria. The cells were fixed with 10% paraformaldehyde in PBS for 30 min, and washed with PBS (1 mL). The bacteria on catheter pieces were stained with DAPI ($1 \mu\text{g mL}^{-1}$) for 20 min and washed again with PBS (1 mL). Confocal imaging was performed on a Leica SP5 confocal microscope using λ_{ex} 405 nm and 414–502 nm emission filter, and images analysed using Image-pro plus 7.0, to obtain percentage of area of bacterial coverage (ESI†).

SEM analysis. SEM imaging was conducted using a Philips XL30 CP electron microscope. After incubation with bacteria, the pieces ($n = 3$) were washed with PBS (2×1 mL) before being transferred into 48-well plates containing 10% formaldehyde in PBS for 30 min. After fixing, the pieces were washed with PBS (1 mL). The catheters were then loaded on stubs, dried overnight at room temperature, and gold coated using a Bal-Tec SCD050 sputter coater prior to imaging.

Results and discussion

High-throughput identification of bacteria repelling polymers

Polymer microarrays with 381 polymer members (each printed in quadruplicate) were fabricated by contact printing of preformed polymers as described previously.²² Individual cultures (*C. jejuni*, *C. difficile*, *C. perfringens*, and *S. mutans*) and two clinically relevant bacteria mixtures, BacMix-1 (consisting of *K. pneumoniae*, *S. saprophyticus* and *S. aureus*) and BacMix-2 (consisting of *K. pneumoniae*, *S. mutans*, *S. aureus*, and *E. faecalis*), were incubated overnight on the arrays. The strains in BacMix-1 and BacMix-2 were obtained from endotracheal tubes from ICU patients or from patients exhibiting infectious endocarditis, often associated with cardiovascular implants. After washing and staining, bacterial adhesion on each of the polymer features was evaluated *via* nucleoid staining, allowing polymer ranking (ESI, Table S1†). Detailed analysis of the arrays showed differences in the bacterial repellence of specific polymers for different strains, with 11 polyacrylates/acrylamides and 11 polyurethanes showing strong repellence for *C. jejuni*, *C. difficile*, *C. perfringens*, and *S. mutans*, as well as the mixtures BacMix-1 and BacMix-2 (ESI, Fig. S1–S8†).

Analysis of the chemical composition of the ‘hit’ polyacrylates/acrylamides revealed some common structural characteristics, with 10 out of the 11 hits containing tertiary amino groups, with aliphatic amines (7 out of the 10) rendering the surface positively charged in biological media. Interestingly, one of the most repellent co-polymers **PA13** (poly(methylmethacrylate-co-dimethylacrylamide)) did not contain amines but contained amide functionalities, neutral at physiological pH. The majority of the best non-binding polyurethanes lacked charged functionalities and were found to contain either poly(butylene glycol)₂₀₀₀ or poly(ethylene glycol)_{900/2000} (ESI, Table S2 and S3†), consistent with the fact that polyglycol groups are known to contribute to resistance to bacterial attachment.^{32,33} Whether the ability of the polymer surface to resist adhesion of bacteria can be predicted from chemical composition of the polymer is an interesting question. Adhesion of bacteria to polymeric surfaces is a result of complex interplay between characteristics of the bacteria, physicochemical properties of the polymer surface and nature of the medium in which the bacteria and the surface interact. In addition, roughness and morphology of the surface affect the adhesion.³⁴ Although there is some vague similarity between the resistant polymers, correlating bacteria resistance to chemical composition of the polymers is problematic,³⁵ further highlighting the advantages of the high-throughput discovery process, which is designed to give leads for further optimisation.

To validate the ‘hits’ and to further explore the bacteria-repellent activity of the polymers on a larger scale, the most promising polyacrylates/acrylamides **PA13**, **PA515**, and **PA338** and polyurethanes **PU5**, **PU20**, **PU83** and **PU179** (see Table 1) were spin-coated onto glass coverslips and assessed for binding by BacMix-1 and BacMix-2. Scanning Electron Microscopy (SEM) was used to quantify the number of bacteria attached to

Table 1 ‘Hit’ polymers used in scaled-up studies

Polymer	Description
PA13	Co-polymer of methylmethacrylate and dimethylacrylamide (9 : 1 monomer ratio) ^a
PA515	Co-polymer of methoxyethylmethacrylate, diethylaminoethylacrylate and methylmethacrylate (6 : 1 : 3 monomer ratio)
PA338	<i>N</i> -Methylaniline functionalised co-polymer of methylmethacrylate and glycidylmethacrylate (1 : 1 monomer ratio)
PU5	Polyurethane synthesised from poly(butylene glycol) ₂₀₀₀ and 1,6-diisocyanatohexane (1 : 1 monomer ratio)
PU20	Polyurethane synthesised from poly(butylene glycol) ₂₀₀₀ and 4,4'-methylenebis(phenylisocyanate) (1 : 1 monomer ratio)
PU83	Polyurethane synthesised from poly(ethylene glycol) ₉₀₀ and 4,4'-methylenebis(cyclohexylisocyanate), with 1,4-butanediol as a chain extender (1 : 2 : 1 monomer ratio)
PU179	Polyurethane synthesised from poly(butylene glycol) ₂₀₀₀ and 1,6-diisocyanatohexane, with 2-nitro-2-methyl-1,3-propanediol as a chain extender (1 : 2 : 1 monomer ratio)

^a Refers to the monomer ratio used in the synthesis of the polymer.



each polymer surface (ESI, Fig. S9 and S10†). Polyacrylates **PA13** and **PA515** and polyurethane **PU83** were found to exhibit the lowest bacteria binding (Fig. 1A and B).

In general, polyacrylates/acrylamides offer a flexible coating material since they can be used either as a solution of pre-formed polymers or synthesised *in situ* on surfaces using a range of polymerisation techniques. Therefore, **PA13** and **PA515** (methoxyethylmethacrylate-*co*-diethylaminoethylacrylate-*co*-methylmethacrylate) were chosen to coat two commercially available types of catheter to study whether the polymers render the surface resistant to bacterial adhesion. Another polyacrylate **PA155** (poly(hydroxyethylmethacrylate-*co*-dimethylaminoethylmethacrylate)), identified in a previous study to offer good bacterial binding,²⁸ was chosen as a control (Fig. 1C). Due to their clinical relevance, BacMix-1 and BacMix-2 were used for binding studies on the coated catheters.

Coating of catheters

A polyurethane-based multi-lumen central intravenous catheter (**Cath-1**) and a silicone-based double lumen catheter (**Cath-2**) were coated and evaluated. The catheters were cut into cylindrical pieces (and the dimensions of the catheter analysed, ESI†) and coated with **PA13**, **PA515**, and the control **PA155**. A range of solvents was evaluated both for their ability to dissolve

the polymers and for compatibility with the catheters. Thus, pieces of catheters were immersed in solvents for 12 h and evaluated for any visual changes (*e.g.* cloudiness or swelling, ESI, Fig. S12†). Both catheter materials tolerated acetone, which due to its low boiling point and fast evaporation, is an ideal solvent to achieve uniform coating. Polymers **PA13**, **PA515** and **PA155** were fully soluble in acetone. Polymer loading on the surfaces was established by treating both **Cath-1** and **Cath-2** with 10% (w/v) **PA13**. **Cath-1-PA13** showed an average weight increase of 36% and **Cath-2-PA13** an average increase of 11%, suggesting that better coating was achieved on **Cath-1**.

Uncoated pieces of **Cath-1** and **Cath-2**, and those coated with polymers **PA13**, **PA515** and **PA155** in acetone, were inoculated with either BacMix-1 or BacMix-2. After incubation, the catheters were washed, and the bacteria fixed and stained with DAPI. Confocal images of the catheter pieces showed significantly improved resistance to bacterial binding on the **PA13** and **PA515** coated catheters, compared to the uncoated catheters (Fig. 2A), whereas coating with control **PA155** resulted in high bacterial binding (data not shown).

Analysis of the confocal images showed that **PA13** had better repellent characteristics than **PA515** (Fig. 2B and C). Reduction in bacterial binding with the polymer coatings varied with the catheter type and bacterial mixture used. For **Cath-1**, coating with **PA515** resulted in 64% reduction in bacterial coverage with




Fig. 1 (A) SEM images of glass and selected polymer surfaces after incubation with bacteria (scale bar = 20 μ m). (B) The average number of bacteria per mm^2 on the polymers, agarose and glass ($n = 4$) after incubation with bacteria. (C) Structures of the random co-polymers **PA13**, **PA515** and **PA155**. The ratio of monomers used in the synthesis is given in the brackets.






Fig. 2 (A) Confocal fluorescence images ($\times 40$ magnification, λ_{ex} 405 nm, λ_{em} 414–502 nm) of catheter surfaces showing bacteria binding/non-binding. The images were obtained after 72 h incubation with bacteria, followed by washing, fixing and staining with DAPI ($1 \mu\text{g mL}^{-1}$). (a and b) uncoated Cath-1, (c and d) uncoated Cath-2, (e and f) Cath-1-PA13, (g and h) Cath-2-PA13, (i and j) Cath-1-PA515, (k and l) Cath-2-PA515. (B) The percentage of surface area covered by bacteria after 72 h incubation with BacMix-1 and BacMix-2, and (C) percentage of reduction in bacteria binding, obtained by comparing the area of bacteria coverage to the area of the image ($n = 3$, see ESI†).




Fig. 3 SEM images of uncoated and coated catheters after incubation with BacMix-1 and BacMix-2 (scale bar = 10 μm). (a and b) Cath-1, (c and d) Cath-1-PA13, (e and f) Cath-2, (g and h) Cath-2-PA13. See ESI† for additional images of Cath-1-PA13 with BacMix-1 (Fig. S14†).



BacMix-2, while coating with PA13 offered $\geq 96\%$ reduction in coverage for both bacterial mixtures. Similarly for Cath-2, coating with PA515 resulted in a moderate 19% reduction in bacterial coverage with BacMix-1, while PA13 coating yielded $\geq 82\%$ reduction with both BacMix-1 and BacMix-2, therefore making PA13 the coating polymer of choice.

SEM analysis was performed to study the reduction of bacterial adhesion on Cath-1-PA13 and Cath-2-PA13. Coated (10% w/v PA13 in acetone) and uncoated catheter pieces were incubated with BacMix-1 and BacMix-2 for 12 days, to mimic the duration of use in a clinical environment. The catheter pieces were then washed, gold coated and imaged. SEM analysis showed that coating with PA13 significantly reduced bacteria binding on the surface of both catheter types (Fig. 3). Also, the surfaces of the coated catheters looked smooth and considerably different from the uncoated catheter surfaces, confirming uniform coating with PA13. The thickness of the polymer coating was measured by cutting the coated catheters and imaging by SEM (ESI, Fig. S13†). Coating with PA13 resulted in a 92 μm and 54 μm layer on Cath-1 and Cath-2, respectively.

Conclusions

A 381-member polymer library was screened on polymer microarrays with bacterial strains (*C. jejuni*, *C. difficile*, *C. perfringens*, and *S. mutans*) and two clinically relevant bacteria mixtures, BacMix-1 (consisting of *K. pneumoniae*, *S. saprophyticus* and *S. aureus*) and BacMix-2 (consisting of *K. pneumoniae*, *S. mutans*, *S. aureus*, and *E. faecalis*). This high-throughput screen identified polyacrylate/acrylamide and polyurethane-based substrates that prevented the adhesion of both Gram-negative and Gram-positive bacteria. Scale-up studies with the two clinically relevant bacterial mixtures revealed that polyurethane PU83 and polyacrylates/acrylamides PA13 and PA515 exhibited broad-spectrum bacteria repellence, suggesting potential for use as coatings for medical devices. PA13 and PA515 were used to uniformly coat both a polyurethane-based and a silicone-based intravenous catheter. Coating with PA13 was found to significantly reduce bacterial binding when compared to uncoated catheters as analysed by confocal microscopy and SEM. This study shows that polymers such as PA13, identified through a high-throughput screening approach, have potential as antibiotic-free bacteria-repellent coatings for medical devices.

Acknowledgements

The authors thank EASTBIO (the East of Scotland BioScience Doctoral Training Partnership funded by the BBSRC) for funding (S. V.). Dr David Kelly of the Wellcome Trust Centre for Cell biology (Optical Instrumentation Laboratory), the SEM facility management at school of geosciences (University of Edinburgh), and Mark Leonard and Dr Robert Thomson (Heriot-Watt University) are thanked for their help with the imaging experiments.

Notes and references

- 1 R. M. Klevens, J. R. Edwards, C. L. Richards, T. C. Horan, R. P. Gaynes, D. A. Pollock and D. M. Cardo, *Public Health Rep.*, 2007, **122**, 160–166.
- 2 K. Inweregbu, J. Dave and A. Pittard, *Continuing Education in Anaesthesia, Critical Care & Pain*, 2005, **5**, 14–17.
- 3 G. Duce, J. Fabry and L. Nicolle, *Prevention of hospital-acquired infections – A practical guide*, WHO, 2002.
- 4 J. W. Costerton, P. S. Stewart and E. P. Greenberg, *Science*, 1999, **284**, 1318–1322.
- 5 R. Wang, B. A. Khan, G. Y. C. Cheung, T. L. Bach, M. Jameson-Lee, K. Kong, S. Y. Queck and M. Otto, *J. Clin. Invest.*, 2011, **121**, 238–248.
- 6 G. O. Toole, H. B. Kaplan and R. Kolter, *Annu. Rev. Microbiol.*, 2000, **54**, 49–79.
- 7 Y. H. An and R. J. Friedman, *Handbook of bacterial adhesion: Principles, methods and applications*, Humana Press, 2000, pp. 73–90 and 581–589.
- 8 Y. H. An and R. J. Friedman, *J. Biomed. Mater. Res., Part B*, 1998, **43**, 338–348.
- 9 P. N. Danese, *Chem. Biol.*, 2002, **9**, 873–880.
- 10 T. F. Mah and G. A. O'Toole, *Trends Microbiol.*, 2001, **9**, 34–39.
- 11 J. P. Guggenbichler, O. Assadian, M. Boeswald and A. Kramer, *GMS Krankenhaushyg. Interdiszip.*, 2011, **6**, 1–19.
- 12 D. Campoccia, L. Montanaro and C. R. Arciola, *Biomaterials*, 2013, **34**, 8533–8554.
- 13 S. Noimark, C. W. Dunnill, M. Wilson and I. P. Parkin, *Chem. Soc. Rev.*, 2009, **38**, 3435–3448.
- 14 E. M. Hetrick and M. H. Schoenfish, *Chem. Soc. Rev.*, 2006, **35**, 780–789.
- 15 M. E. Rupp, S. J. Lisco, P. A. Lipsett, T. M. Perl, K. Keating, J. M. Civetta, L. A. Mermel, D. Lee, E. P. Dellinger, M. Donahoe, D. Giles, M. A. Pfaller, D. G. Maki and R. Sherertz, *Ann. Intern. Med.*, 2005, **143**, 570–580.
- 16 J. Greenfeld, L. Sampath, S. Popilskis, S. Brunnert, S. Stylianou and S. Modak, *Crit. Care Med.*, 1995, **23**, 894–900.
- 17 R. Tcholakian and I. I. Raad, *Antimicrob. Agents Chemother.*, 2001, **45**, 1990–1993.
- 18 X. Ding, C. Yang, T. P. Lim, L. Y. Hsu, A. C. Engler, J. L. Hedrick and Y.-Y. Yang, *Biomaterials*, 2012, **33**, 6593–6603.
- 19 F. Peng, E. M. V. Hoek and R. Damoiseaux, *J. Biomol. Screening*, 2010, **15**, 748–754.
- 20 S. J. Stafslin, J. A. Bahr, J. M. Feser, J. C. Weisz, B. J. Chisholm, T. E. Ready and P. Boudjouk, *J. Comb. Chem.*, 2006, **8**, 156–162.
- 21 T. T. Nyame, K. P. Lemon, R. Kolter and E. C. Liao, *Plast. Reconstr. Surg.*, 2011, **128**, 1061–1068.
- 22 G. Tourniaire, J. Collins, S. Campbell, H. Mizomoto, S. Ogawa, J.-F. Thaburet and M. Bradley, *Chem. Commun.*, 2006, 2118–2120.
- 23 D. G. Anderson, S. Levenberg and R. Langer, *Nat. Biotechnol.*, 2004, **22**, 863–866.
- 24 R. Zhang, A. Liberski, R. Sanchez-Martin and M. Bradley, *Biomaterials*, 2009, **30**, 6193–6201.



- 25 R. Zhang, H. K. Mjoseng, M. A. Hoeve, N. G. Bauer, S. Pells, R. Besseling, S. Velugotla, G. Tourniaire, R. E. B. Kishen, Y. Tsenkina, C. Armit, C. R. E. Duffy, M. Helfen, F. Edenhofer, P. A. de Sousa and M. Bradley, *Nat. Commun.*, 2013, **4**(1335), 1–10.
- 26 C. R. E. Duffy, R. Zhang, S.-E. How, A. Lilienkampf, P. A. de Sousa and M. Bradley, *Biomaterials*, 2014, **35**, 5998–6005.
- 27 A. Hansen, L. McMillan, A. Morrison, J. Petrik and M. Bradley, *Biomaterials*, 2011, **32**, 7034–7041.
- 28 S. Pernagallo, M. Wu, M. P. Gallagher and M. Bradley, *J. Mater. Chem.*, 2011, **21**, 96–101.
- 29 A. L. Hook, C.-Y. Chang, J. Yang, J. Lockett, A. Cockayne, S. Atkinson, Y. Mei, R. Bayston, D. J. Irvine, R. Langer, D. G. Anderson, P. Williams, M. C. Davies and M. R. Alexander, *Nat. Biotechnol.*, 2012, **30**, 868–875.
- 30 H. Pickering, M. Wu, M. Bradley and H. Bridle, *Environ. Sci. Technol.*, 2012, **46**, 2179–2186.
- 31 M. Wu, H. Bridle and M. Bradley, *Water Res.*, 2012, **46**, 1715–1722.
- 32 P. Kingshott, J. Wei, D. Bagge-Ravn, N. Gadegaard, L. Gram and D. Lyngby, *Langmuir*, 2003, **209**, 6912–6921.
- 33 K. D. Park, Y. S. Kim, D. K. Han, Y. H. Kim, E. H. Lee, H. Suh and K. S. Choi, *Biomaterials*, 1998, **19**, 851–859.
- 34 P. Decuzzi and M. Ferrari, *Biomaterials*, 2010, **31**, 173–179.
- 35 H. H. Tuson and D. B. Weibel, *Soft Matter*, 2013, **9**, 4368–4380.

